An investor consortium including CICC Qianhai Development (Shenzhen) Fund Management, CITIC M&A Fund Management Co., Ltd., and a number of Chinese bio-industry companies and investment firms, has agreed to privatize NASDAQ-listed Chinese biopharmaceutical products provider Sinovac Biotech Ltd., at the valuation of around US$401.8 million.
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Read 2 Articles for Free with a Basic Account
Gain limited and restricted access to China Money Network.Register Basic Account
Subscribe for an annual subscription!
Enjoy comprehensive and exclusive data you can't find elsewhere!More Info
Already have an account or paid subscription?